Charlotte, North Carolina–(Newsfile Corp. – May 24, 2024) – cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBD-PA) (the “Company”) is thrilled to announce the launch of its highly anticipated ATRx Labs Premium Mushroom Line, available exclusively at GNC stores nationwide. Crafted with a blend of powerful mushroom extracts, derived from the fruiting bodies of the mushrooms and complimented by clinically studied ingredients, these supplements are designed to cater to a wide array of health needs for consumers across the nation.
As consumers increasingly seek natural alternatives to support their well-being, cbdMD has answered the call with its new ATRx Labs Premium Mushroom Line. Harnessing the power of nature’s powerhouse functional mushrooms, each product in the line is meticulously formulated to address specific health needs, from supporting healthy cognitive and immune function to caffeine-free focus and healthy weight management.
“We are excited to introduce our exclusive Premium Mushroom Line at GNC, a trusted destination for quality health and wellness products,” said Ronan Kennedy, CEO and CFO at cbdMD. “Our team has worked tirelessly to develop these cutting-edge supplements, leveraging the growing body of science around functional mushrooms to deliver effective and natural solutions for our customers.”
The Premium Mushroom Line includes four distinct products, each designed to offer unique benefits:
This exclusive range of products are currently only available at GNC stores nationwide, offering customers convenient access to these innovative health supplements.
“We believe that everyone deserves access to premium supplements that are safe, effective, and backed by science,” continued Kennedy. “Our partnership with GNC helps us make this vision a reality. To address the growing consumer demand, cbdMD developed ATRx Labs which is focused on cutting-edge health and wellness products without cannabinoids or CBD.”
As both companies look forward to the positive impact this collaboration will have on consumers nationwide, they remain dedicated to setting new standards in the health and nutrition industry.
For more information about ATRx Labs, visit atrxlabs.com. Engage on social at @ATRx_Labs.
About cbdMD, Inc.:
cbdMD, Inc. is one of the leading and most highly trusted and most recognized Cannabidiol (CBD) brands with a comprehensive line of U.S. produced, THC-free1 CBD products, including NSF Certified for Sport® products, as well as a wide array of Full Spectrum products. Our cbdMD brand currently includes high-grade, premium CBD products including CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD sleep aids, and a growing collection of Farm Act compliant Delta 9 products. Our Paw CBD brand of pet products includes veterinarian-formulated products including tinctures and chews in varying strengths, and our ATRx Labs brand of natural functional mushroom support. To learn more about cbdMD and our comprehensive line of U.S. grown, THC-free1 CBD oil and Full Spectrum products as well as our other brands, please visit www.cbdmd.com, www.pawcbd.com, or ATRxLabs.com, follow cbdMD on Instagram and Facebook, or visit one of the thousands of retailers nationwide that carry cbdMD’s products.
Forward-Looking Statements:
This press release contains certain forward-looking statements that are based upon current expectations and involve certain risks and uncertainties within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements can be identified using words such as ”should,” ”may,” ”intends,” ”anticipates,” ”believes,” ”estimates,” ”projects,” ”forecasts,” ”expects,” ”plans,” and ”proposes.” These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict. You are urged to carefully review and consider any cautionary statements, including but not limited to our collaboration with GNC, federal and state regulation of dietary supplement products, and other disclosures, including the statements made under the heading “Risk Factors” in cbdMD, Inc.’s Annual Report on Form 10-K for the fiscal year ended September 30, 2023as filed with the Securities and Exchange Commission (the “SEC”) and our other filings with the SEC. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, many of which are generally outside the control of cbdMD, Inc. and are difficult to predict. cbdMD, Inc. does not undertake any duty to update any forward-looking statements except as may be required by law. The information which appears on our websites and our social media platforms, including, but not limited to, Instagram and Facebook, is not part of this press release.
Contact Information:
cbdMD, Inc.
Ronan Kennedy, Interim CEO & CFO
+1 (704) 445-3064
IR@cbdmd.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/210252
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading…
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading…
SEATTLE, June 4, 2024 /PRNewswire/ -- AffableBPM, a leader in AI-powered business process automation for…
Azenta has been Selected by the Crohn's & Colitis Foundation as its Sample Management Services…
MedISAO's Large Language Model-based approach will allow organizations to maintain the ability to manage and…
Fmr. White House COVID Response Chief Dr. Ashish K. Jha leads dynamic roster of healthcare…